Biologic Drug Survival in Pediatric Psoriasis: A Retro-Prospective Observational Study

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Irrational selection of biological therapy leads to its inefficiency and early cancellation, aggravating the course of psoriasis and worsening the quality of life, which has negative socio-economic consequences associated with the cost of initiating and providing the patient with a new biological agent. Currently there are no clearly defined strategies and unified protocols for therapeutic tactics regarding the choice and switching of biological drugs in children with psoriasis, which requires research aimed at studying the survival of biological therapy in order to draw up evidence-based recommendations with a high evidence base. Aims — study aims to determine survival rate and significant predictors of biological therapy discontinuation. Methods. A retro-prospective observational study was conducted, which included patients with psoriasis vulgaris, aged 4 to 18 years, who had previously received or needed biological therapy. The data of patients over an 8-year period (from 2015 to 2023) were analyzed. Follow-up was performed from initiation to discontinuation of biological therapy, in cases where outcomes were unknown data was censored. Analysis of therapy survival was carried out using the Kaplan–Meier method with curve construction, the assessment of intergroup differences was carried out using a log rank test. Identification of significant predictors of biological therapy discontinuation was carried out using the Cox multivariate regression method. Results. 430 cases of biological therapy were selected from patients with psoriasis vulgaris aged 5 to 18 years. The highest survival rate of biological therapy was obtained for ustekinumab — 54.9 months, the lowest values — for etanercept (26.7 months). The survival values of adalimumab — 33.9 months and secukinumab — 34.5 months did not statistically significantly differ from each other (p = 0.387). Predictors of early discontinuation of biological therapy were established: presence of a burdened family history (HR = 3.861, p = 0.006); delayed prescription of biological therapy — > 2 years from the date of diagnosis (HR = 1.447, p = 0.045); long-term (> 6 months) use of methotrexate (HR = 3.085, p < 0.001) or cyclosporine (HR = 4.538, p < 0.001) previous to the biological treatment; the presence of comorbidity (inflammatory bowel diseases (HR = 4.938, p = 0.001), metabolic syndrome (HR = 3.947, p < 0.001) or psoriatic arthritis (HR = 2.337, p < 0.001). Conclusions. Proved the inexpediency of long-term immunosuppressive treatment with non-biological drugs and the need for early prescription of biological therapy. In the presence of a burdened family history and disease duration > 2 years since the diagnosis of psoriasis, ustekinumab or secukinumab are recommended as first-line biological therapy in children, the use of which is also associated with a longer duration of treatment and a lower risk of developing adverse events in patient with metabolic syndrome. In active Crohn’s disease, adalimumab is most recommended, followed by a possible switch to ustekinumab. Secukinumab is the drug of choice for patients diagnosed with psoriatic arthritis.

Full Text

Restricted Access

About the authors

Nikolay N. Murashkin

National Medical Research Center of Children’s Health; I.M. Sechenov First Moscow State Medical University (Sechenov University); Central State Medical Academy of Department of Presidential Affairs

Author for correspondence.
Email: m_nn2001@mail.ru
ORCID iD: 0000-0003-2252-8570
SPIN-code: 5906-9724

MD, PhD, Professor

Russian Federation, Moscow; Moscow; Moscow

Roman A. Ivanov

National Medical Research Center of Children’s Health; Central State Medical Academy of Department of Presidential Affairs

Email: isxiks@gmail.com
ORCID iD: 0000-0002-0081-0981
SPIN-code: 5423-8683

MD

Russian Federation, Moscow; Moscow

References

  1. Gunter NV, Yap BJM, Chua CLL, et al. Combining Understanding of Immunological Mechanisms and Genetic Variants Toward Development of Personalized Medicine for Psoriasis Patients. Front Genet. 2019;10:395. doi: https://doi.org/10.3389/fgene.2019.00395
  2. Мурашкин Н.Н., Круглова Л.С., Коваленко Ю.А., и др. Коморбидности псориаза в детском возрасте // Вопросы современной педиатрии. — 2020. — Т. 19. — № 6. — С. 460–467. [Murashkin NN, Kruglova LS, Kovalenko IA, et al. Psoriasis Comorbidities in Childhood. Current Pediatrics. 2020;19(6):460–467. (In Russ.)] doi: https://doi.org/10.15690/vsp.v19i6.2149
  3. Paller AS, Schenfeld J, Accortt NA, et al. A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population. Pediatr Dermatol. 2019;36(3):290–297. doi: https://doi.org/10.1111/pde.13772
  4. Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study. Front Med (Lausanne). 2021;8:743180. doi: https://doi.org/10.3389/fmed.2021.743180
  5. Branisteanu DE, Georgescu S, Serban IL, et al. Management of psoriasis in children (Review). Exp Therc Med. 2021;22(6):1429. doi: https://doi.org/10.3892/etm.2021.10864
  6. Elvina M. Pediatric Psoriasis: Clinical Features and Course. Open Access Journal of Biomedical Science. 2020;2(1):207–209. doi: https://doi.org/10.38125/OAJBS.000147
  7. Torrelo A. The use of biologics for childhood psoriasis. J Eur Acad Dermatol Venereol. 2019;33(10):1816. doi: https://doi.org/10.1111/jdv.15855
  8. Мурашкин Н.Н., Амбарчян Э.Т. Сравнительная оценка эффективности и безопасности ингибиторов TNFα и IL12/23 в терапии псориаза у детей // Педиатрическая фармакология. — 2018. — Т. 15. — № 6. — С. 455–463. [Murashkin NN, Ambarchian ET. Comparative Evaluation of the Treatment Efficacy and Safety of TNFα and IL12/23 Inhibitors in Children with Psoriasis. Pediatric pharmacology. 2018;15(6):455–463. (In Russ.)] doi: https://doi.org/10.15690/pf.v15i6.1983
  9. Мурашкин Н.Н., Амбарчян Э.Т., Епишев Р.В., и др. Эффективность и безопасность устекинумаба у детей с бляшечной, эритродермической и ладонно-подошвенной формами псориаза: ретроспективное когортное исследование // Вопросы современной педиатрии. — 2020. — Т. 19. — № 6. — С. 531–537. [Murashkin NN, Ambarchian ET, Epishev RV, et al. Ustekinumab Efficacy and Safety in Children with Plaque, Erythrodermic and Palmoplanar Forms of Psoriasis: Retrospective Cohort Study. Current Pediatrics. 2020;19(6):531–537. (In Russ.)] doi: https://doi.org/10.15690/vsp.v19i6.2153
  10. Намазова-Баранова Л.С., Бакулев А.Л., Мурашкин Н.Н., и др. Лечение среднетяжелого и тяжелого псориаза у детей: новые возможности генно-инженерной биологической терапии // Вопросы современной педиатрии. — 2021. — Т. 20. — № 5. — С. 446–450. [Namazova-Baranova LS, Bakulev AL, Murachkin NN, et al. Management of Moderate and Severe Forms of Psoriasis in Children: New Opportunities of Genetically Engineered Biologic Drugs. Current Pediatrics. 2021;20(5):446–450. (In Russ.)] doi: https://doi.org/10.15690/vsp.v20i5.2322
  11. Иванов Р.А., Мурашкин Н.Н. Выживаемость биологической терапии у детей, страдающих псориазом: когортное исследование // Вопросы современной педиатрии. — 2021. — Т. 20. — № 5. — С. 451–458. [Ivanov RA, Murashkin NN. Biological Therapy Survivability in Children with Psoriasis: Cohort Study. Current Pediatrics. 2021;20(5):451–458. (In Russ.)] doi: https://doi.org/10.15690/vsp.v20i5.2323
  12. Lin P-T, Wang S-H, Chi C-C. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep. 2018;8(1):16068. doi: https://doi.org/10.1038/s41598-018-34293-y
  13. Иванов Р.А., Мурашкин Н.Н. Особенности применения генно-инженерной биологической терапии (устекинумаб) у детей с псориазом при наличии сопутствующего метаболического синдрома или неэффективности предшествующей биологической терапии: клинические наблюдения // Вопросы современной педиатрии. — 2022. — Т. 21. — № 5. — С. 419–429. [Ivanov RA, Murashkin NN. Administration Details of Genetically Engineered Biologic Drug (Ustekinumab) in Children with Psoriasis and Comorbid Metabolic Syndrome or in Case of Previous Biological Therapy Failure: Case Studies. Current Pediatrics. 2022;21(5):419–429. (In Russ.)] doi: https://doi.org/10.15690/vsp.v21i5.2458
  14. Иванов Р.А. Важность и перспективы изучения выживаемости генно-инженерной биологической терапии при псориазе у детей // Медицинский алфавит. — 2022. — № 8. — С. 80–85. [Ivanov RA. Importance and prospects of studying survival of genetically engineered biological therapy for psoriasis in children. Medical alphabet. 2022;8:80–85. (In Russ.)] doi: https://doi.org/10.33667/2078-5631-2022-8-80-85
  15. Псориаз у детей и взрослых: клинические рекомендации. — М., 2020. — 66 с. [Psoriaz u detej i vzroslyh: klinicheskie rekomendacii. Moscow; 2020. 66 s. (In Russ.)]
  16. Круглова Л.С., Осина А.В., Хотко А.А. Биологическая терапия в лечении псориаза: понятие «выживаемость» препаратов. Обзор литературы // КМКВ. — 2018. — № 3. — С. 191–196. [Kruglova LS, Osina AV, Chotko АА. Biological therapy in the treatment of psoriasis: the concept of drugs survival. Review. Kremlevskaya medicina. Klinicheskij vestnik. 2018;3:191–196. (In Russ.)]
  17. No DJ, Inkeles MS, Amin M, et al. Drug survival of biologic treatments in psoriasis: a systematic review. J Dermatolog Treat. 2018;29(5):460–466. doi: https://doi.org/10.1080/09546634.2017.1398393
  18. Phan C., Beauchet A., Burztejn A-C, et al. Biological treatments for paediatric psoriasis (BiPe): A retrospective observational study on biological drug survival in daily practice in childhood psoriasis. Eur J Acad Dermatol Venereol. 2019;33(10):1984–1992. doi: https://doi.org/10.1111/jdv.15579
  19. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10. doi: https://doi.org/10.1007/s00403-010-1080-1
  20. Mrowietz U, Steinz K, Gerdes S. Psoriasis: to treat or to manage? Exp Dermatol. 2014;23(10):705–709. doi: https://doi.org/10.1111/exd.12437
  21. Yiu ZZN, Mason KJ, Hampton PJ, et al. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2020;183(2):294–302. doi: https://doi.org/10.1111/bjd.18981
  22. Egeberg A, Rosenø NAL, Aagaard D, et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis — A nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53:151979. doi: https://doi.org/10.1016/j.semarthrit.2022.151979
  23. Jacobi A, Rustenbach SJ, Augustin M. Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis. Int J Dermatol. 2016;55(3):296–302. doi: https://doi.org/10.1111/ijd.12879
  24. Warren RB, Smith CH, Yiu ZZN, et al. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632–2640. doi: https://doi.org/10.1038/jid.2015.208
  25. Graier T, Salmhofer W, Jonak C, et al. Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis. Br J Dermatol. 2021;184(6):1094–1105. doi: https://doi.org/10.1111/bjd.19701
  26. Antoniou C, Dessinioti C, Stratigos A, et al. Etanercept in severe, recalcitrant psoriasis: clinical response, safety profile and predictors of response based on a single institution’s experience. J Eur Acad Dermatol Venereol. 2009;23(8):979–982. doi: https://doi.org/10.1111/j.1468-3083.2009.03093.x
  27. Akdogan N, Dogan S, Bostan E, et al. Age and psoriatic arthritis are important predictors of biologic agent switch in psoriasis. Expert Rev Clin Pharmacol. 2021;14(12):1535–1541. doi: https://doi.org/10.1080/17512433.2021.1979394
  28. Galache Osuna C, Gómez-Vila B, Aubán Pariente J, et al. Ustekinumab Drug Survival in Patients with Psoriasis: A retrospective Study of Real Clinical Practice. Medicina. 2020;56(11):584. doi: https://doi.org/10.3390/medicina56110584
  29. Cheuk S, Wikén M, Blomqvist L, et al. Epidermal Th22 and Tc17 Cells Form a Localized Disease Memory in Clinically Healed Psoriasis. J Immunol. 2014;192(7):3111–3120. doi: https://doi.org/10.4049/jimmunol.1302313
  30. Fujiyama T, Umayahara T, Kurihara K, et al. Skin Infiltration of Pathogenic Migratory and Resident T Cells Is Decreased by Secukinumab Treatment in Psoriasis. J Invest Dermatol. 2020;140(10):2073–2076.e6. doi: https://doi.org/10.1016/j.jid.2020.02.024
  31. Benezeder T, Wolf P. Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease). Semin Immunopathol. 2019;41(6):633–644. doi: https://doi.org/10.1007/s00281-019-00766-z
  32. Sbidian E, Mezzarobba M, Weill A, et al. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-naïve patients from the French National Health Insurance database (SNIIRAM). Br J Dermatol. 2019;180(1):86–93. doi: https://doi.org/10.1111/bjd.16809
  33. Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148–1158. doi: https://doi.org/10.1111/jdv.13611
  34. Shalom G, Cohen AD, Ziv M, et al. Biologic drug survival in Israeli psoriasis patients. J Am Acad Dermatol. 2017;76(4):662–669.e1. doi: https://doi.org/10.1016/j.jaad.2016.10.033

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig.1. Flowchart of the selection process for cases receiving genetically engineered biological therapy. Note. GEBT - genetic engineering biological therapy; GIBP is a genetically engineered biological drug.

Download (508KB)
Indexing metadata
3. Fig.2. Kaplan–Meier survival curves of genetically engineered biological therapy depending on the biological agent received by patients. Note. GIBT is genetic engineering biological therapy.

Download (118KB)
Indexing metadata
4. Fig.3. Adjusted Kaplan–Meier survival curves for genetically engineered biological therapy taking into account the influence of statistically significant predictors of discontinuation. Note. GIBT is genetic engineering biological therapy.

Download (114KB)
Indexing metadata
5. Fig.4. Survival curves of therapy depending on the biological naivety of patients, taking into account the genetically engineered biological drug received in bionaive patients (A) and patients who previously received biological therapy (B). Note. GIBT is genetic engineering biological therapy.

Download (183KB)
Indexing metadata
6. Fig.5. Survival curves of genetically engineered biological therapy depending on whether the patient has a family history of psoriasis in patients without a family history of psoriasis (A) and patients with a family history of psoriasis (B). Note. GIBT is genetic engineering biological therapy.

Download (186KB)
Indexing metadata
7. Fig.6. Survival curves of genetic engineering biological therapy in the general sample of cases depending on the presence of comorbid pathologies in the patient (two comorbidities: a combination of psoriatic arthritis and metabolic syndrome). Note. GIBT is genetic engineering biological therapy.

Download (138KB)
Indexing metadata
8. Fig.7. Survival curves of genetically engineered biological therapy depending on previously received nonbiological systemic treatment. Note. GIBT is genetic engineering biological therapy.

Download (147KB)
Indexing metadata

Copyright (c) 2023 "Paediatrician" Publishers LLC



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies